Market research
MEDCL.PA MedinCell S.A
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 873M
- P/E ratio
- Not available
- Analyst target
- 34.5111
- Dividend yield
- Not available
- Beta
- 0.98
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0004065605
- Market cap
- 873M
- P/E ratio
- Not available
- Analyst target
- 34.5111
- Dividend yield
- Not available
- Beta
- 0.98
About
About MedinCell S.A
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MEDCL.PA discussion.
5 years, 4 months ago
MedinCell S.A is currently in a long term downtrend where the price is trading 18.1% below its 200 day moving average.
From a valuation standpoint, the stock is 58.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 112.3.
MedinCell S.A's total revenue sank by 0.0% to $2M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.3% to $-3M since the same quarter in the previous year.
Based on the above factors, MedinCell S.A gets an overall score of 2/5.